United Therapeutics
UTHR
334 hedge funds and large institutions have $7.13B invested in United Therapeutics in 2014 Q4 according to their latest regulatory filings, with 54 funds opening new positions, 93 increasing their positions, 147 reducing their positions, and 36 closing their positions.
50% more first-time investments, than exits
New positions opened: 54 | Existing positions closed: 36
5% more funds holding
Funds holding: 319 → 334 (+15)
5% more capital invested
Capital invested by funds: $6.8B → $7.13B (+$336M)
4% more call options, than puts
Call options by funds: $39.2M | Put options by funds: $37.8M
28% less funds holding in top 10
Funds holding in top 10: 18 → 13 (-5)
37% less repeat investments, than reductions
Existing positions increased: 93 | Existing positions reduced: 147
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Scopia Capital Management
New York
|
+$41.6M |
| 2 |
AQR Capital Management
Greenwich,
Connecticut
|
+$41.6M |
| 3 |
D.E. Shaw & Co
New York
|
+$32.3M |
| 4 |
IAM
Iridian Asset Management
Westport,
Connecticut
|
+$30.4M |
| 5 |
First Trust Advisors
Wheaton,
Illinois
|
+$27.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HCM
Herndon Capital Management
Atlanta,
Georgia
|
-$145M |
| 2 |
Schroder Investment Management Group
London,
United Kingdom
|
-$87.6M |
| 3 |
WG
Winton Group
London,
United Kingdom
|
-$48.4M |
| 4 |
AL
AJO LP
Philadelphia,
Pennsylvania
|
-$39.3M |
| 5 |
Los Angeles Capital Management
Los Angeles,
California
|
-$32.4M |
UTHR Hedge Fund Activity: Q4 2014 in Review
334 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in United Therapeutics (UTHR) for Q4 2014, worth a combined $7.13B — up 4.9% from $6.8B a quarter earlier.
Buyers outnumbered sellers: 54 funds opened new UTHR positions and 36 closed out — a net gain of 18 holders — while 93 added to existing stakes and 147 trimmed.
The largest buyer was Scopia Capital Management, adding an estimated $41.6M. The largest seller was Herndon Capital Management, cutting an estimated $145M.
- 334 institutional investors held United Therapeutics (UTHR) as of Q4 2014, up from 319 in Q3 2014.
- Funds reported $7.13B of United Therapeutics stock for Q4 2014, up 4.9% quarter-over-quarter.
- 54 funds opened new United Therapeutics positions in Q4 2014 and 36 closed out, a net change of +18 holders.
- The largest United Therapeutics buyer in Q4 2014 was Scopia Capital Management, an estimated $41.6M added.
- The largest United Therapeutics seller in Q4 2014 was Herndon Capital Management, an estimated $145M sold.
Based on aggregated 13F filings for Q4 2014.